Drugs / Zandelisib
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03985189 | Apr 2019 → Jan 2025 | indolent B-cell non-Hodgkin lymphoma | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02914938 | Oct 2016 → Mar 2023 | chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, high grade B-cell lymphoma, mantle cell lymphoma +1 | MEI Pharma, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT02521389 | Jun 2015 → Feb 2017 | cancer | MEI Pharma, Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05604417 | Jan 2023 → Dec 2024 | follicular lymphoma | Jacob Soumerai, MD | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04517435 | Apr 2021 → May 2023 | diffuse large B-cell lymphoma | Deepa Jagadeesh | Terminated | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05209308 | Nov 2022 → Mar 2023 | chronic lymphocytic leukemia/small lymphocytic lymphoma | MEI Pharma, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT04533581 | Sep 2020 → May 2028 expected | indolent B-cell non-Hodgkin lymphoma | Kyowa Kirin, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03768505 | Jun 2019 → Mar 2023 | follicular lymphoma, marginal zone lymphoma | MEI Pharma, Inc. | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04745832 | Aug 2021 → Mar 2023 | follicular lymphoma, marginal zone lymphoma | MEI Pharma, Inc. | Terminated | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | zandelisib | “Zandelisib, a selective, potent PI3Kδ inhibitor, demonstrated favourable outcomes in patients with relapsed or refractory follicular lymphoma in a global phase II study.” PMID 39778876 ↗ Jan 20255“Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin's lymphoma: an open-label, multicenter, dose-escalation phase 1 study.” PMID 36107394 ↗ Sep 2022 |
| Known as | ACC-524 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650214 ↗ |
| Known as | ME-401 | “Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin's lymphoma: an open-label, multicenter, dose-escalation phase 1 study.” PMID 36107394 ↗ Sep 20223“This is the study of the PI3Kδ inhibitor Zandelisib (ME-401) in subjects with relapsed/refractory follicular lymphoma or marginal zone lymphoma” NCT03768505 ↗ |
| Known as | PW-143 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650214 ↗ |
| Known as | PWT-143 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02521389 ↗ |
| Action | Inhibit | “PI3-kinase p110-delta subunit inhibitor” CHEMBL4650214 ↗1“PI3Kδ inhibitor Zandelisib (ME-401)” NCT03768505 ↗ |
| Modality | Small molecule | — CHEMBL4650214 ↗ |
| Route | Oral | “will be administered 60 mg of ME-401 orally” NCT03768505 ↗ |
| Target | PIK3CD | “PI3-kinase p110-delta subunit inhibitor” CHEMBL4650214 ↗ |